Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch Health Companies (BHC – Research Report), National Health Investors (NHI – Research Report) and ARS Pharmaceuticals (SPRY – Research Report).
Bausch Health Companies (BHC)
Jefferies analyst Glen Santangelo upgraded Bausch Health Companies to Buy today and set a price target of $16.00. The company’s shares closed last Tuesday at $7.72.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $9.20.
See today’s best-performing stocks on TipRanks >>
National Health Investors (NHI)
Jefferies analyst Jonathan Petersen initiated coverage with a Hold rating on National Health Investors today and set a price target of $52.00. The company’s shares closed last Tuesday at $50.58.
According to TipRanks.com, Petersen is a 5-star analyst with an average return of
Currently, the analyst consensus on National Health Investors is a Hold with an average price target of $55.33.
ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals received a Hold rating from William Blair analyst Tim Lugo today. The company’s shares closed last Tuesday at $6.61.
According to TipRanks.com, Lugo is ranked #710 out of 8562 analysts.
Currently, the analyst consensus on ARS Pharmaceuticals is a Moderate Buy with an average price target of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BHC:
